{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:08:37Z","timestamp":1790366917444,"version":"4.1.0"},"reference-count":29,"publisher":"Media Sphere Publishing House","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Burdenko's Journal of Neurosurgery"],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:p>According to the modern WHO classification, pituitary carcinomas (or metastatic neuroendocrine pituitary tumors) are pituitary tumors with confirmed craniospinal and\/or distant metastases. The main goal of histological analysis of pituitary carcinomas is to confirm pituitary origin of metastases. Treatment usually includes surgery and radiotherapy, dopamine agonists in maximum possible doses in case of prolactin-secreting pituitary carcinomas and chemotherapy with preferable temozolomide. Objective. To present the results of diagnosis and treatment of two patients with prolactin-secreting pituitary carcinomas. Material and methods. The authors describe 2 patients with prolactin-secreting pituitary carcinomas arising from drug-resistant aggressive prolactinomas with histologically confirmed metastases. In both cases, combined treatment included surgery, radio- and chemotherapy (cabergoline and temozolomide). Results. A 47-year-old patient underwent surgery, radio- and dopamine agonist therapy with subsequent regression of tumor growth in the follow-up period. However, progressive increase in prolactin concentration necessitated PET\/CT with detection of multiple metastases in bones and lymph nodes. Temozolomide therapy led to temporary shrinkage of metastatic foci with subsequent progression. The second case was characterized by multiple brain and spinal cord metastases in a 47-year-old woman. Resection of intracranial metastasis and temozolomide therapy stabilized the disease and normalized serum prolactin throughout 2-year follow-up with subsequent progression. Conclusion. Pituitary carcinoma is a rare tumor with unfavorable prognosis. Treatment is currently not standardized and determined by available world experience regarding various chemotherapeutic drugs. Temozolomide is the most effective drug. However, short-term remission is usually followed by subsequent disease progression in most cases.<\/jats:p>","DOI":"10.17116\/neiro20258901183","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T15:46:18Z","timestamp":1738770378000},"page":"83","source":"Crossref","is-referenced-by-count":2,"title":["Prolactin-secreting pituitary carcinomas with intra- and extracranial metastasis: case report and review"],"prefix":"10.17116","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-1902","authenticated-orcid":false,"given":"L.I.","family":"Astafieva","sequence":"first","affiliation":[{"name":"Burdenko Neurosurgical Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9789-3452","authenticated-orcid":false,"given":"I.V.","family":"Chernov","sequence":"additional","affiliation":[{"name":"Burdenko Neurosurgical Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-4214","authenticated-orcid":false,"given":"G.L.","family":"Kobyakov","sequence":"additional","affiliation":[{"name":"Botkin Moscow Multidisciplinary Scientific Clinical Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4240-5036","authenticated-orcid":false,"given":"Yu.Yu.","family":"Trunin","sequence":"additional","affiliation":[{"name":"Burdenko Neurosurgical Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7045-7223","authenticated-orcid":false,"given":"L.V.","family":"Shishkina","sequence":"additional","affiliation":[{"name":"Burdenko Neurosurgical Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-3115","authenticated-orcid":false,"given":"A.N.","family":"Shkarubo","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-1000","authenticated-orcid":false,"given":"D.V.","family":"Fomichev","sequence":"additional","affiliation":[{"name":"Burdenko Neurosurgical Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2733-5874","authenticated-orcid":false,"given":"Yu.G.","family":"Sidneva","sequence":"additional","affiliation":[{"name":"Research Institute of Emergency Pediatric Surgery and Traumatology","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8493-7893","authenticated-orcid":false,"given":"G.R.","family":"Vagapova","sequence":"additional","affiliation":[{"name":"Kazan State Medical Academy","place":["Kazan, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-9473","authenticated-orcid":false,"given":"P.L.","family":"Kalinin","sequence":"additional","affiliation":[{"name":"Burdenko Neurosurgical Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/neiro20258901183-1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac010"},{"key":"key-10.17116\/neiro20258901183-2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.07.014"},{"key":"key-10.17116\/neiro20258901183-3","doi-asserted-by":"publisher","DOI":"10.1007\/s00062-011-0073-6"},{"key":"key-10.17116\/neiro20258901183-4","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1683435"},{"key":"key-10.17116\/neiro20258901183-5","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0021"},{"key":"key-10.17116\/neiro20258901183-6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2012.06.009"},{"key":"key-10.17116\/neiro20258901183-7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2231"},{"key":"key-10.17116\/neiro20258901183-8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0872-8"},{"key":"key-10.17116\/neiro20258901183-9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.968692"},{"key":"key-10.17116\/neiro20258901183-10","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-16-0038"},{"key":"key-10.17116\/neiro20258901183-11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005268"},{"key":"key-10.17116\/neiro20258901183-12","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3"},{"key":"key-10.17116\/neiro20258901183-13","doi-asserted-by":"publisher","DOI":"10.3171\/foc.2004.16.4.8"},{"key":"key-10.17116\/neiro20258901183-14","doi-asserted-by":"publisher","DOI":"10.4103\/jnrp.jnrp_325_17"},{"key":"key-10.17116\/neiro20258901183-15","unstructured":"Astafieva LI, Kadashev BA, Trunin YuYu, Rotin DL. Development of \u2018secondary\u2019 resistance to dopamine agonists in a patient with giant prolactinoma. Burdenko\u2019s Journal of Neurosurgery. 2010;4:48-51. (In Russ.)"},{"key":"key-10.17116\/neiro20258901183-16","doi-asserted-by":"publisher","DOI":"10.3171\/foc.2004.16.4.8"},{"key":"key-10.17116\/neiro20258901183-17","unstructured":"Guastamacchia E, Triggiani V, Tafaro E, De Tommasi A, De Tommasi C, Luzzi S, Sabb\u00e0 C, Resta F, Terreni MR, Losa M. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report. Minerva Endocrinology. 2007;32:231-6"},{"key":"key-10.17116\/neiro20258901183-18","unstructured":"Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Research. 1987;47:5846-52"},{"key":"key-10.17116\/neiro20258901183-19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055665"},{"key":"key-10.17116\/neiro20258901183-20","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2006.105.4.621"},{"key":"key-10.17116\/neiro20258901183-21","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2012(Sup01)20"},{"key":"key-10.17116\/neiro20258901183-22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4350"},{"key":"key-10.17116\/neiro20258901183-23","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1991-y"},{"key":"key-10.17116\/neiro20258901183-24","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0979"},{"key":"key-10.17116\/neiro20258901183-25","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/587893"},{"key":"key-10.17116\/neiro20258901183-26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0933"},{"key":"key-10.17116\/neiro20258901183-27","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1729"},{"key":"key-10.17116\/neiro20258901183-28","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0796"},{"key":"key-10.17116\/neiro20258901183-29","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030088"}],"container-title":["Burdenko's Journal of Neurosurgery"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T15:46:58Z","timestamp":1738770418000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-voprosy-nejrokhirurgii-imeni-n-n-burdenko\/2025\/1\/1004288172025011083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2,5]]}},"alternative-id":["10.17116\/neiro20258901183"],"URL":"https:\/\/doi.org\/10.17116\/neiro20258901183","relation":{},"ISSN":["0042-8817"],"issn-type":[{"value":"0042-8817","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}